Skip to content
MARKETS / NASDAQ / ECOR
NASDAQ · ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS · SMALL CAP

electroCore, Inc. ECOR

9 fiscal years on record · USD · FY2025 reported · SEC filings only
$32.0M
▲ 27.2% YoY
$-14.0M
$-8.3M
In brief

What this company does

Our business generates revenues from the sale of prescription medical devices and non-prescription wellness products in the United States and select overseas markets. As of February 1, 2026, we employed 83 full-time employees. None of our employees are represented by a labor union or covered by a collective bargaining agreement. On May 1, 2025 (the “NURO Closing Date”), the Company completed its previously announced acquisition of NeuroMetrix pursuant to the terms of the Agreement and Plan of Merger dated as of December 17, 2024 (the “Merger Agreement”) by and among the Company, NURO, and Nexus Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of the Company (“Merger Sub”).

Written from the business description in electroCore, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 19 March 2026. Every sentence was checked against that document before publication.

Growth
USD 32.0M
Revenue, FY2025 · full 9-year series below
Revenue $M Net income $M
FY2025 · Revenue 32.0 · Net income -14.0
20M-20M-40M201720182019202020212022202320242025
Compound annual growth
+55.1%
+55.7%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +55.7% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−44 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -41.1% · Net -43.6%
-2000%-4000%201720182019202020212022202320242025
ROE
FY2025 · ROE -478.7%
-200%-400%201720182019202020212022202320242025

Each USD of equity lost 479 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -8.3
-20M-40M201720182019202020212022202320242025

Total assetsUSD 18.7M
EquityUSD -1.7M
CashUSD 7.0M
Gross debtUSD 6.6M
Net debtUSD -428,000.00
Current ratio1.38×

Equity was negative — liabilities exceeded assets. No ratio is shown.

The 9-year record
9 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 202520242023202220212020201920182017
Revenue $B0.00.00.00.00.00.00.00.00.0
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.1−0.0
EBITDA $B·−0.0−0.0−0.0−0.0−0.0−0.0−0.1−0.0
Income tax $B0.0−0.0−0.0−0.0−0.0−0.00.00.0·
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.1−0.0
Free cash flow $B−0.0·−0.0···−0.0−0.0−0.0
EPS, diluted $−1.65−1.59−3.42−4.69−4.36−0.60−1.54−1.19·
Dividend / sh $·········
Payout %·········
ROE %−478.7−158.6−153.6−82.5−57.7−99.5−100.5··
Shares out B0.010.010.010.000.000.050.030.030.00

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 1 failures in 44 reconciliationsAUDITED

Reconciled in 8 of 19 fiscal years. 51 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente1 failures
ActivityElectromedical & Electrotherapeutic Apparatus
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2017

Share this section

Download image